Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices 7281 

Dated: February 12, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–3036 Filed 2–17–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Translating 

Research Into Action for Diabetes 

(TRIAD) Legacy Study, Funding 

Opportunity Announcement (FOA) DP 

10–005, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 11 a.m.–5 p.m., March 31, 

2010 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘TRIAD Legacy Study, FOA DP 

10–005.’’ 

Contact Person for More Information: Don 

Blackman, PhD, Scientific Review Officer, 

National Center for Chronic Disease and 

Health Promotion, Office of the Director, 

Extramural Research Program Office, 4770 

Buford Highway, NE., Mailstop K–92, 

Atlanta, GA 30341, telephone: (770) 488– 

3023, e-mail: DBlackman@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 10, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3064 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Injury Prevention 

and Control/Initial Review Group, 

(NCIPC/IRG) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned review group: 

Time and Date: 12:30 p.m.–4 p.m., 

March 3, 2010 (closed). 

Place: Teleconference. 

Status: The meetings will be closed to 

the public in accordance with 

provisions set forth in Section 

552b(c)(4) and (6), Title 5, U.S.C., and 

the Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Section 10(d) 

of Public Law 92–463. 

Purpose: This group is charged with 

providing advice and guidance to the 

Secretary, Department of Health and 

Human Services, and the Director, CDC, 

concerning the scientific and technical 

merit of grant and cooperative 

agreement applications received from 

academic institutions and other public 

and private profit and nonprofit 

organizations, including State and local 

government agencies, to conduct 

research that will build the scientific 

base for the prevention of unintentional 

poisonings from drug overdoses in the 

adult population. 

Matters to be Discussed: The meeting 

will include the review, discussion, and 

evaluation of applications intended to 

encourage exploratory/developmental 

research in unintentional childhood 

injury. Requests for Applications are 

related to the following individual 

research announcement: CE10–002 

Unintentional Poisoning from 

Prescription Drug Overdoses in Adults 

(R21). 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

J. Felix Rogers, PhD, M.P.H., Telephone 

(770) 488–4334, NCIPC, CDC, 4770 

Buford Highway, NE., Mail Stop F63, 

Atlanta, Georgia 30341–3724. The 

Director, Management Analysis and 

Services Office has been delegated the 

authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

the Agency for Toxic Substances and 

Disease Registry. 

Dated: February 4, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3047 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Pediatric Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on Monday, March 22, 2010, from 

8 a.m. to 6 p.m. 

Location: Bethesda Marriott Hotel, 

5151 Pooks Hill Rd., Bethesda, MD., 

20814. 

Contact Person: Doreen Kezer, Office 

of the Commissioner, Food and Drug 

Administration, 5600 Fishers Lane (HF– 

33), rm. 14–65, Rockville, MD 20857, 

301–827–1249, e-mail: 

Doreen.Kezer@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732310001. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: The Pediatric Advisory 

Committee will meet to discuss 

pediatric-focused safety reviews, as 

mandated by the Best Pharmaceuticals 

for Children Act and the Pediatric 

Research Equity Act, for: Anthelios 40, 

Cardiolite (technetium Tc-99), Nasacort 

AQ (triamcinolone), Viramune 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

7282 Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices 

(nevirapine), Valtrex (valacyclovir), 

Zmax (azithromycin), Rotarix (rotavirus 

vaccine, live, oral), Kinrix (Diphtheria 

and Tetanus Toxoids and Acellular 

Pertussis Adsorbed and Inactivated 

Poliovirus Vaccine), Pentacel 

[Diphtheria and Tetanus Toxoids and 

Acellular Pertussis Adsorbed, 

Inactivated Poliovirus and Haemophilus 

b Conjugate (Tetanus Toxoid Conjugate) 

Vaccine], and Daptacel (Diphtheria and 

Tetanus Toxoids and Acellular Pertussis 

Vaccine Adsorbed vaccine). The 

committee will also receive an update 

on Topical Calcineurin Inhibitors: Elidel 

(pimecrolimus) and Protopic 

(tacrolimus). Also, the committee will 

receive a brief followup on the FDA 

Early Communication about reports of 

liver-related adverse events in patients 

taking orlistat (marketed as Alli and 

Xenical). 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before March 8, 2010. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before February 28, 2010. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

March 1, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Doreen 

Kezer, at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: February 4, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–3024 Filed 2–17–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Breast and Cervical Cancer Early 

Detection and Control Advisory 

Committee (BCCEDCAC) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following committee 

meeting: 

Times and Dates: 12 p.m.–5 p.m., March 

15, 2010. 8:30 a.m.–5 p.m., March 16, 2010. 

8:30 a.m.–3 p.m., March 17, 2010. 

Place: Crowne Plaza Atlanta Perimeter at 

Ravinia, 4355 Ashford Dunwoody Road, 

Atlanta, GA 30346, Telephone: 770–395– 

7700. 

Status: Open to the public, limited only by 

the number of seats available. 

Purpose: The committee is charged with 

advising the Secretary, Department of Health 

and Human Services, and the Director, CDC, 

regarding the early detection and control of 

breast and cervical cancer. The committee 

makes recommendations regarding national 

program goals and objectives; 

implementation strategies; and program 

priorities including surveillance, 

epidemiologic investigations, education and 

training, information dissemination, 

professional interactions and collaborations, 

and policy. 

Matters To Be Discussed: The agenda will 

include discussion and review of U.S. 

Preventive Services Task Force guidelines for 

breast and cervical cancer screening; Impact 

of the revised clinical screening 

recommendations for both breast and cervical 

cancer on the National Breast and Cervical 

Cancer Early Detection Program; Discussion 

of what, if any, modifications should be 

made to the NBCCEDP’s current screening 

policies based on revised recommendations. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: Dr. 

Chastity Walker, Designated Federal Officer, 

BCCEDCAC, Division of Cancer Prevention 

and Control, National Center for Chronic 

Disease Prevention and Health Promotion, 

CDC, 4770 Buford Highway, Mailstop K–57, 

Chamblee, Georgia 30316, Telephone: 770– 

488–3013. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 3, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–3143 Filed 2–17–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Circulatory System Devices Panel of 

the Medical Devices Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Circulatory 

System Devices Panel of the Medical 

Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on March 18 and 19, 2010, from 8 

a.m. to 6 p.m. 

Location: College Park Holiday Inn, 

Grand Ballroom, 10000 Baltimore Ave., 

College Park, MD. 

Contact Person: James Swink, Center 

for Devices and Radiological Health, 

Food and Drug Administration, 10903 

New Hampshire Ave., Silver Spring, MD 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES